You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Boehringer Ingelheim Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Drugs and US Patents for Boehringer Ingelheim

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim JENTADUETO linagliptin; metformin hydrochloride TABLET;ORAL 201281-001 Jan 30, 2012 AB RX Yes No 9,155,705*PED ⤷  Try a Trial Y ⤷  Try a Trial
Boehringer Ingelheim STRIVERDI RESPIMAT olodaterol hydrochloride SPRAY, METERED;INHALATION 203108-001 Jul 31, 2014 RX Yes Yes 7,727,984 ⤷  Try a Trial Y ⤷  Try a Trial
Boehringer Ingelheim RANITIDINE HYDROCHLORIDE ranitidine hydrochloride TABLET;ORAL 074662-002 Aug 29, 1997 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate CAPSULE;ORAL 022512-003 Nov 20, 2015 AB RX Yes No 7,932,273*PED ⤷  Try a Trial Y ⤷  Try a Trial
Boehringer Ingelheim TRIJARDY XR empagliflozin; linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 212614-001 Jan 27, 2020 RX Yes No 9,949,998*PED ⤷  Try a Trial Y ⤷  Try a Trial
Boehringer Ingelheim PERSANTINE dipyridamole TABLET;ORAL 012836-005 Feb 6, 1987 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Boehringer Ingelheim

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim GLYXAMBI empagliflozin; linagliptin TABLET;ORAL 206073-002 Jan 30, 2015 8,119,648 ⤷  Try a Trial
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-001 May 27, 2016 6,488,962 ⤷  Try a Trial
Boehringer Ingelheim TRADJENTA linagliptin TABLET;ORAL 201280-001 May 2, 2011 8,178,541 ⤷  Try a Trial
Boehringer Ingelheim MICARDIS HCT hydrochlorothiazide; telmisartan TABLET;ORAL 021162-002 Nov 17, 2000 6,358,986 ⤷  Try a Trial
Boehringer Ingelheim STRIVERDI RESPIMAT olodaterol hydrochloride SPRAY, METERED;INHALATION 203108-001 Jul 31, 2014 5,964,416 ⤷  Try a Trial
Boehringer Ingelheim MEXITIL mexiletine hydrochloride CAPSULE;ORAL 018873-002 Dec 30, 1985 4,031,244 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 0.75 mg ➤ Subscribe 2008-07-31
➤ Subscribe Inhalation Powder Capsules 18 mcg ➤ Subscribe 2018-05-11
➤ Subscribe Tablets 5 mg/500 mg5 mg/1000 mg12.5 mg/500 mg12.5 mg/1000 mg ➤ Subscribe 2018-08-01
➤ Subscribe Extended-release Tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg ➤ Subscribe 2010-06-01
➤ Subscribe Extended-release Tablets 5 mg/1000 mg10 mg/1000 mg12.5 mg/1000 mg25 mg/1000 mg ➤ Subscribe 2018-08-01
➤ Subscribe Tablets 20 mg, 30 mg and 40 mg ➤ Subscribe 2017-07-12
➤ Subscribe Tablets 10 mg and 25 mg ➤ Subscribe 2018-08-01
➤ Subscribe Tablets 20 mg, 40 mg and 80 mg ➤ Subscribe 2006-12-26
➤ Subscribe Tablets 80 mg/25 mg ➤ Subscribe 2009-02-27
➤ Subscribe Capsules 100 mg and 150 mg ➤ Subscribe 2018-10-15
➤ Subscribe Tablets 0.25 mg ➤ Subscribe 2005-05-27
➤ Subscribe Capsules eq. to 110 mg base ➤ Subscribe 2015-12-15
➤ Subscribe Oral Suspension 7.5 mg/5 mL ➤ Subscribe 2009-12-17
➤ Subscribe Extended-releaseTablets 2.5 mg/1000 mg 5 mg/1000 mg ➤ Subscribe 2018-03-28
➤ Subscribe Tablets 5 mg ➤ Subscribe 2015-05-04
➤ Subscribe Extended-release Tablets 2.25 mg and 3.75 mg ➤ Subscribe 2011-07-26
➤ Subscribe Extended-release Tablets 400 mg ➤ Subscribe 2013-06-21
➤ Subscribe Tablets 10 mg/5 mg and 25 mg/5 mg ➤ Subscribe 2018-08-01
➤ Subscribe Tablets 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg ➤ Subscribe 2015-05-04
➤ Subscribe Tablets 80 mg/12.5 mg and 40 mg/12.5 mg ➤ Subscribe 2008-12-31
➤ Subscribe Extended-release Capsules 25 mg and 200 mg ➤ Subscribe 2007-02-01
➤ Subscribe Tablets 0.125 mg, 0.5 mg, 1 mg and 1.5 mg ➤ Subscribe 2005-06-24
➤ Subscribe Capsules eq. to 75 mg base and 150 mg base ➤ Subscribe 2014-10-20

Supplementary Protection Certificates for Boehringer Ingelheim Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0565634 06C0030 France ⤷  Try a Trial PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0503785 CA 2011 00026 Denmark ⤷  Try a Trial PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
2187879 132017000050485 Italy ⤷  Try a Trial PRODUCT NAME: COMBINAZIONE DI EMPAGLIFLOZIN E LINAGLIPTIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(GLYXAMBI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1146, 20161115
1345910 92370 Luxembourg ⤷  Try a Trial PRODUCT NAME: AFATINIB,LES TAUTOMERES,LES STEREOISOMERES ET LES SELS DE CELUI-CI,DES SELS PHYSIOLOGIQUEMENT ACCEPTABLES DE CELUI-CI AVEC DES ACIDES OU BASES ORGANIQUES OU INORGANIQUES,DE PREFERENCE UN SEL MALEATE DE CELUI-CI,ET PLUS DE PREFERENCE UN SEL DIMALEATE DE CELUI-CI
1830843 300747 Netherlands ⤷  Try a Trial PRODUCT NAME: NINTEDANIB, OF EEN TAUTOMEER, DE MENGSELS DAARVAN OF EEN ZOUT DAARVAN; IN HET BIJZONDER NINTEDANIBESILAAT; REGISTRATION NO/DATE: EU/1/14/979 20150115
1730131 SPC/GB14/070 United Kingdom ⤷  Try a Trial PRODUCT NAME: EMPAGLIFLOZIN AND SALTS THEREOF; REGISTERED: UK EU/1/14/930/001 - 20140527; UK EU/1/14/930/018 20140527
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.